Susquehanna International Group
ZVRA icon

Susquehanna International Group’s Zevra Therapeutics ZVRA Stock Holding History

Susquehanna International Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$610K Buy
65,400
+40,500
+163% +$365K ﹤0.01% 9151
2025
Q4 		$223K Sell
24,900
-77,900
-76% -$737K ﹤0.01% 10636
2025
Q3 		$978K Sell
102,800
-374,300
-78% -$3.75M ﹤0.01% 7419
2025
Q2 		$4.2M Buy
477,100
+177,800
+59% +$1.44M ﹤0.01% 4304
2025
Q1 		$2.24M Buy
+299,300
New +$2.38M ﹤0.01% 5272
2024
Q4 		– Sell
-198,500
Closed -$1.38M – 13394
2024
Q3 		$1.38M Buy
198,500
+177,800
+859% +$1.21M ﹤0.01% 6106
2024
Q2 		$101K Sell
20,700
-5,500
-21% -$26.1K ﹤0.01% 11023
2024
Q1 		$152K Sell
26,200
-35,200
-57% -$216K ﹤0.01% 10894
2023
Q4 		$402K Sell
61,400
-14,200
-19% -$66.4K ﹤0.01% 9165
2023
Q3 		$364K Sell
75,600
-41,900
-36% -$209K ﹤0.01% 8944
2023
Q2 		$599K Buy
117,500
+10,100
+9% +$54.4K ﹤0.01% 7887
2023
Q1 		$591K Sell
107,400
-114,600
-52% -$606K ﹤0.01% 8169
2022
Q4 		$1.02M Sell
222,000
-66,700
-23% -$339K ﹤0.01% 6148
2022
Q3 		$1.8M Sell
288,700
-11,500
-4% -$65.1K ﹤0.01% 5134
2022
Q2 		$1.34M Buy
300,200
+43,800
+17% +$200K ﹤0.01% 5819
2022
Q1 		$1.29M Buy
256,400
+43,000
+20% +$274K ﹤0.01% 6499
2021
Q4 		$1.86M Buy
213,400
+29,400
+16% +$262K ﹤0.01% 5682
2021
Q3 		$1.72M Sell
184,000
-21,300
-10% -$215K ﹤0.01% 6177
2021
Q2 		$2.63M Sell
205,300
-57,100
-22% -$614K ﹤0.01% 5319
2021
Q1 		$2.41M Buy
+262,400
New +$2.29M ﹤0.01% 5453
2019
Q2 		– Sell
-769
Closed -$21K – 10936
2019
Q1 		$21K Buy
+769
New +$28.3K ﹤0.01% 8588

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Susquehanna International Group's ZVRA Position: Q1 2026 in Review

Susquehanna International Group reduced its Zevra Therapeutics (ZVRA) stake by 36% in Q1 2026, selling an estimated $960K and leaving 186,582 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #6504.

Susquehanna International Group first reported a position in ZVRA in Q4 2015 and has held it in 32 quarters since. The position peaked at $11.5M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Susquehanna International Group held 186,582 shares of Zevra Therapeutics worth $1.74M as of Q1 2026.
  • Susquehanna International Group sold 106,513 Zevra Therapeutics shares in Q1 2026, an estimated $960K.
  • Zevra Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6504 holding.
  • Susquehanna International Group first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Susquehanna International Group's Zevra Therapeutics position peaked at $11.5M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.